|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: MOLECULAR DEVICES CORP, 10-Q, EX-10.24, 2000-11-13 |
Next: PHARMACEUTICAL PRODUCT DEVELOPMENT INC, 10-Q, 2000-11-13 |
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION FROM THE CONDENSED
CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2000 AND THE CONSOLIDATED
STATEMENT OF INCOME FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> SEP-30-2000
<CASH> 32,214
<SECURITIES> 70,003
<RECEIVABLES> 22,055
<ALLOWANCES> 481
<INVENTORY> 12,379
<CURRENT-ASSETS> 150,604
<PP&E> 16,690
<DEPRECIATION> 8,411
<TOTAL-ASSETS> 165,660
<CURRENT-LIABILITIES> 16,153
<BONDS> 0
0
0
<COMMON> 16
<OTHER-SE> 149,140
<TOTAL-LIABILITY-AND-EQUITY> 165,660
<SALES> 68,558
<TOTAL-REVENUES> 68,558
<CGS> 25,413
<TOTAL-COSTS> 25,413
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (5,410)
<INCOME-TAX> 3,762
<INCOME-CONTINUING> (9,172)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (9,172)
<EPS-BASIC> (0.61)
<EPS-DILUTED> (0.61)
</TABLE>
|
|